Patent · US Active

Certain protein kinase inhibitors

US10022374B2 · kind B2 · utility

0Cited by

1References

13Claims

0Family size

Assignee

Shanghai Fochon Pharmaceutical Co., Ltd. · CN

Inventors

Weibo Wang · Moraga, US
Xingdong Zhao · Chongqing, CN
Quan Yuan · Xiamen, CN
Hailong Shi · Chongqing, CN
Qiang Tian · Sichuan, CN
Qihong LIU · Chongqing, CN
Zuwen Zhou · Chongqing, CN
Xianlong Wang · Chongqing, CN
Zhifang Chen · Tangxia, CN
Ling Chen · Shanghai, CN
Haohan TAN · Chongqing, CN
Bo Fang · Chongqing, CN
Lihua Jiang · Beijing, CN
Yanxin Liu · Chongqing, CN
Jing Sun · Suzhou, CN
Fanxin Zeng · Chongqing, CN
Tongshuang Li · Surrey, CA

Key dates

Filing date	Dec 15, 2016
Grant date	Jul 17, 2018
Priority date	—
Expiry date	Dec 15, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are protein kinase inhibitors, more particularly pyridazine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.